Pathalys Pharma Closes $105M Series B Financing Round

Pathalys Pharma Inc., a private biopharmaceutical company in the late stages of developing treatments for kidney disease, has successfully closed a $105 million Series B financing round led by TCGX and joined by other notable investors including, JP Morgan Life Sciences Private Capital, Samsara BioCapital, Marshall Wace, KB Investment, JPS Growth Investment Limited Partnership, plus support from Pathalys’ founding investors, Catalys Pacific and DaVita Venture Group. 
 
“Since our inception, Pathalys has made significant strides toward our goal of delivering a best-in-class treatment for those with end-stage kidney disease (ESKD), including the near completion of two phase 3 clinical trials for upacicalcet,” said Neal Fowler, CEO at Pathalys Pharma, Inc. “We believe the continued expansion of our syndicate of prominent life science investors, with representative board members, is indicative of the fact that we are on the right path at Pathalys.  We are immensely grateful for the continued support of our investors and remain steadfast and confident in our mission to bring upacicalcet forward to patients.”
 
The funds will be utilized to finalize the two ongoing upacicalcet clinical trials, execution of the NDA filing process with the U.S. Food and Drug Administration (FDA), and acceleration of preapproval commercialization preparations.  Joining the Board of Directors as members will be Dr. Chen Yu and Mr. Joe Siletto, Managing Partner of JP Morgan Life Sciences Private Capital.  Additionally, Dr. Roger Zhang, Ph.D. of Samsara BioCapital will join the Board as an observer.

More Pathalys News